Personalis Appoints Clinton Musil as Chief Business Officer
January 03, 2019 at 02:59 pm
Share
Personalis, Inc. announced the appointment of Clinton Musil as Chief Business Officer. Mr. Musil will focus initially on financing strategy. As a member of Personalis’ executive team he will also participate actively in the company’s global strategic planning, and approach to broader business relationships. Prior to joining ARMO, Mr. Musil was a Managing Director at Hercules Capital where he provided capital to life sciences companies at multiple stages of development.
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.